Jess C. Mace

Mar 29, 2025 | onlinelibrary.wiley.com | Christine Liu |Jakob Fischer |Michelle Lee |Jess C. Mace

1 Introduction Chronic rhinosinusitis (CRS) is common in people with cystic fibrosis (PwCF), with the majority of adults with CF presenting with radiologic sinus inflammation and sinonasal symptoms [1, 2]. Olfactory dysfunction (OD) is a cardinal symptom of CRS, a commonly reported sequela of sinus disease, and up to 90% of adults with CF may have OD [3, 4].

Jun 22, 2024 | onlinelibrary.wiley.com | Christine Liu |Jonathan B. Overdevest |Anna C. Zemke |Jess C. Mace

No abstract is available for this article. BIBLIOGRAPHY 1, , , et al. Predictors of sinonasal improvement after highly effective modulator therapy in adults with cystic fibrosis. Laryngoscope. 2024. https://doi.org/10.1002/lary.31438. 2, , , et al. Elexacaftor-tezacaftor-ivacaftor improves sinonasal outcomes in cystic fibrosis. J Cyst Fibros. 2022; 21(5): 792-799. https://doi.org/10.1016/j.jcf.2022.03.002. 3, , , et al.